This post is co-written with Kim Nguyen and Shyam Banuprakash from Clario. Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies seeking to bring new therapies to patients. Since Clario’s founding more than 50 years ago, theContinue Reading
In the rapidly evolving healthcare landscape, patients often find themselves navigating a maze of complex medical information, seeking answers to their questions and concerns. However, accessing accurate and comprehensible information can be a daunting task, leading to confusion and frustration. This is where the integration of cutting-edge technologies, such asContinue Reading
Traditionally, clinical trials not only place a significant burden on patients and participants due to the costs associated with transportation, lodging, meals, and dependent care, but also have an environmental impact. With the advancement of available technologies, decentralized clinical trials have become a widely popular topic of discussion and offerContinue Reading
Sundry Photography/iStock Editorial via Getty Images Prelude Therapeutics (NASDAQ:PRLD) has forged a deal with Merck (NYSE:MRK) to test its investigational SMARCA2 degrader in combination with the latter’s blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with SMARCA4-mutated cancers. Shares of Prelude Therapeutics (PRLD) climbed as much as 28% following the news.Continue Reading
Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ) has discontinued a Phase 2 trial for its blockbuster arthritis therapy Tremfya in patients with an autoimmune disorder called giant cell arteritis after the study failed to meet the primary goal, according to updated data from a federal register ofContinue Reading
